Nearly Half of Surveyed Specialists Expect to Prescribe Gilead's Sofosbuvir/Ledipasvir Regimen Near-Term for Hepatitis C Infections

Nearly Half of Surveyed Specialists Expect to Prescribe Gilead's Sofosbuvir/Ledipasvir Regimen Near-Term for Hepatitis C Infections

BURLINGTON, Mass., Aug. 19, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of hepatitis C virus (HCV) infections, 40 percent of surveyed HCV treating specialists expect to prescribe Gilead's investigational fixed-dose combination of sofosbuvir/ledipasvir in the next six months to their genotype 1 patients. Analysis of surveyed specialists' near-term prescribing intent indicates that nearly one in every four actively treated genotype 1 patients will be prescribed the sofosbuvir/ledipasvir regimen in the next six months. However, the on-treatment patient shares for the off-label Olysio (Janssen) and Sovaldi combination regimen are expected to remain stable over this period.

About Decision Resources Group Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact: Decision Resources Group Christopher Comfort 781-993-2597 [email protected]
Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?